The role of tenascin C in cardiovascular disease

Cardiovascular Research

Volumn 92, Issue 1, 2011, Pages 19-28

  Golledge, Jonathan ^a   Clancy, Paula ^a   Maguire, Jane ^b   Lincz, Lisa ^c   Koblar, Simon ^d  

^a JAMES COOK UNIVERSITY   (Australia)

^b UNIVERSITY OF NEWCASTLE   (Australia)

^c CALVARY MATER NEWCASTLE HOSPITAL   (Australia)

^d UNIVERSITY OF ADELAIDE   (Australia)

Author keywords

Cardiovascular disease; Extracellular matrix protein; Tenascin C

Indexed keywords

SCLEROPROTEIN; TENASCIN; VASCULAR CELL ADHESION MOLECULE 1;

ARTERY INTIMA PROLIFERATION; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; DIAGNOSTIC VALUE; GENETIC POLYMORPHISM; HEART DISEASE; HEART INFARCTION; HEART MUSCLE BIOPSY; HUMAN; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INTERACTION; PROTEIN STRUCTURE; PULMONARY HYPERTENSION; REVIEW; UPREGULATION;

ANIMALS; CARDIOVASCULAR DISEASES; HUMANS; POLYMORPHISM, SINGLE NUCLEOTIDE; SIGNAL TRANSDUCTION; TENASCIN;

EID: 80052904942     PISSN: 00086363     EISSN: 17553245     Source Type: Journal    
DOI: 10.1093/cvr/cvr183     Document Type: Review

References (102)

1. Jones PL, Jones FS. Tenascin-C in development and disease: gene regulation and cell function. Matrix Biol 2000;19:581-596.
2. Hsia HC, Schwarzbauer JE. Meet the tenascins: multifunctional and mysterious. J Biol Chem 2005;280:26641-26644. (Pubitemid 41040694)
3. von Holst A. Tenascin C in stem cell niches: redundant, permissive or instructive? Cells Tissues Organs 2008;188:170-177. (Pubitemid 351962240)
4. Saga Y, Yagi T, Ikawa Y, Sakakura T, Aizawa S. Mice develop normally without tenascin. Genes Dev 1992;6:1821-1831.
5. Wang M, Ihida-Stansbury K, Kothapalli D, Tamby MC, Yu Z, Chen L et al. Microsomal prostaglandin e2 synthase-1 modulates the response to vascular injury. Circulation 2011;123:631-639.
6. Goh FG, Piccinini AM, Krausgruber T, Udalova IA, Midwood KS. Transcriptional regulation of the endogenous danger signal tenascin-C: a novel autocrine loop in inflammation. J Immunol 2010;184:2655-2662.
7. Cohen ED, Ihida-Stansbury K, Lu MM, Panettieri RA, Jones PL, Morrisey EE. Wnt signalling regulates smooth muscle precursor development in the mouse lung via a tenascin C/PDGFR pathway. J Clin Invest 2009;119:2538-2549.
8. Kim DK, Lee SC, Lee HW. CD137 ligand-mediated reverse signals increase cell viability and cytokine expression in murine myeloid cells: involvement of mTOR/p70S6 kinase and Akt. Eur J Immunol 2009;39:2617-2628.
9. Ihida-Stansbury K, McKean DM, Lane KB, Loyd JE, Wheeler LA, Morrell NW et al. Tenascin-C is induced by mutated BMP type II receptors in familial forms of pulmonary arterial hypertension. Am J Physiol Lung Cell Mol Physiol 2006;291:L694-L702. (Pubitemid 44498481)
10. Ballard VL, Sharma A, Duignan I, Holm JM, Chin A, Choi R et al. Vascular tenascin-C regulates cardiac endothelial phenotype and neovascularization. FASEB J 2006;20: 717-719. (Pubitemid 46671192)
11. Sisbarro L, Ihida-Stansbury K, Stevens T, Bauer N, McMurtry I, Jones PL. The extracellular matrix microenvironment specifies pulmonary endothelial cell identity: roles of tenascin-C and RhoA. Chest 2005;128:564S. (Pubitemid 43054118)
12. Gratchev A, Kzhyshkowska J, Utikal J, Goerdt S. Interleukin-4 and dexamethasone counterregulate extracellular matrix remodelling and phagocytosis in type-2 macrophages. Scand J Immunol 2005;61:10-17. (Pubitemid 40188343)
13. Feng Y, Yang JH, Huang H, Kennedy SP, Turi TG, Thompson JF et al. Transcriptional profile of mechanically induced genes in human vascular smooth muscle cells. Circ Res 1999;85:1118-1123. (Pubitemid 30430615)
14. Cattaruzza M, Lattrich C, Hecker M. Focal adhesion protein zyxin is a mechanosensitive modulator of gene expression in vascular smooth muscle cells. Hypertension 2004;43:726-730. (Pubitemid 38405578)
15. Fujinaga K, Onoda K, Yamamoto K, Imanaka-Yoshida K, Takao M, Shimono T et al. Locally applied cilostazol suppresses neointimal hyperplasia by inhibiting tenascin-C synthesis and smooth muscle cell proliferation in free artery grafts. J Thorac Cardiovasc Surg 2004;128:357-363. (Pubitemid 39194689)
16. LaFleur DW, Fagin JA, Forrester JS, Rubin SA, Sharifi BG. Cloning and characterization of alternatively spliced isoforms of rat tenascin. Platelet-derived growth factor-BB markedly stimulates expression of spliced variants of tenascin mRNA in arterial smooth muscle cells. J Biol Chem 1994;269:20757-20763.
17. Mackie EJ, Scott-Burden T, Hahn AW, Kern F, Bernhardt J, Regenass S et al. Expression of tenascin by vascular smooth muscle cells. Alterations in hypertensive rats and stimulation by angiotensin II. Am J Pathol 1992;141:377-388.
18. Jones FS, Meech R, Edelman DB, Oakey RJ, Jones PL. Prx1 controls vascular smooth muscle cell proliferation and tenascin-C expression and is upregulated with Prx2 in pulmonary vascular disease. Circ Res 2001;89:131-138. (Pubitemid 34135820)
19. Jones PL, Jones FS, Zhou B, Rabinovitch M. Induction of vascular smooth muscle cell tenascin-C gene expression by denatured type I collagen is dependent upon a beta3 integrin-mediated mitogen-activated protein kinase pathway and a 122-base pair promoter element. J Cell Sci 1999;112:435-445. (Pubitemid 29106191)
20. Jones PL, Crack J, Rabinovitch M. Regulation of tenascin-C, a vascular smooth muscle cell survival factor that interacts with the alpha v beta 3 integrin to promote epidermal growth factor receptor phosphorylation and growth. J Cell Biol 1997;139: 279-293. (Pubitemid 27444098)
21. Hahn AW, Kern F, Jonas U, John M, Bühler FR, Resink TJ. Functional aspects of vascular tenascin-C expression. J Vasc Res 1995;32:162-174.
22. Sharifi BG, LaFleur DW, Pirola CJ, Forrester JS, Fagin JA. Angiotensin II regulates tenascin gene expression in vascular smooth muscle cells. J Biol Chem 1992;267: 23910-23915. (Pubitemid 23088203)
23. Jin L, Hastings NE, Blackman BR, Somlyo AV. Mechanical properties of the extracellular matrix alter expression of smooth muscle protein LPP and its partner palladin; relationship to early atherosclerosis and vascular injury. J Muscle Res Cell Motil 2009;30:41-55.
24. Schöber W, Tran QB, Muringaseril M, Wiskirchen J, Kehlbach R, Rodegerdts E et al. Impact of glafenine hydrochloride on human endothelial cells and human vascular smooth muscle cells: a substance reducing proliferation, migration and extracellular matrix synthesis. Cell Biol Int 2003;27:987-996. (Pubitemid 37463530)
25. Johst U, Betsch A, Wiskirchen J, Schöber W, Vonthein R, Rinkert N et al. All-trans and 9-cis retinoid acids inhibit proliferation, migration, and synthesis of extracellular matrix of human vascular smooth muscle cells by inducing differentiation in vitro. J Cardiovasc Pharmacol 2003;41:526-535. (Pubitemid 36373789)
26. Ichii T, Koyama H, Tanaka S, Kim S, Shioi A, Okuno Y et al. Fibrillar collagen specifically regulates human vascular smooth muscle cell genes involved in cellular responses and the pericellular matrix environment. Circ Res 2001;88:460-467. (Pubitemid 32240908)
27. Tavazoie SF, Alarcón C, Oskarsson T, Padua D, Wang Q, Bos PD et al. Endogenous human microRNAs that suppress breast cancer metastasis. Nature 2008;451: 147-152.
28. Sumioka T, Fujita N, Kitano A, Okada Y, Saika S. Impaired angiogenic response in the cornea of mice lacking tenascin C. Invest Ophthalmol Vis Sci 2011;52:2462-2467.
29. Schaff M, Receveur N, Bourdon C, Wurtz V, Denis CV, Orend G et al. Novel function of tenascin-C, a matrix protein relevant to atherosclerosis, in platelet recruitment and activation under flow. Arterioscler Thromb Vasc Biol 2011;31:117-124.
30. Saito Y, Shiota Y, Nishisaka M, Owaki T, Shimamura M, Fukai F. Inhibition of angiogenesis by a tenascin-c peptide which is capable of activating beta1-integrins. Biol Pharm Bull 2008;31:1003-1007. (Pubitemid 351731977)
31. Wallner K, Li C, Shah PK, Wu KJ, Schwartz SM, Sharifi BG. EGF-Like domain of tenascin-C is proapoptotic for cultured smooth muscle cells. Arterioscler Thromb Vasc Biol 2004;24:1416-1421. (Pubitemid 39050434)
32. Castellon R, Caballero S, Hamdi HK, Atilano SR, Aoki AM, Tarnuzzer RW et al. Effects of tenascin-C on normal and diabetic retinal endothelial cells in culture. Invest Ophthalmol Vis Sci 2002;43:2758-2766. (Pubitemid 34809470)
33. Wallner K, Shah PK, Sharifi BG. Balloon catheterization induces arterial expression of new Tenascin-C isoform. Atherosclerosis 2002;161:75-83. (Pubitemid 34214823)
34. Imanaka-Yoshida K, Hiroe M, Nishikawa T, Ishiyama S, Shimojo T, Ohta Y et al. Tenascin-C modulates adhesion of cardiomyocytes to extracellular matrix during tissue remodeling after myocardial infarction. Lab Invest 2001;81:1015-1024. (Pubitemid 32645977)
35. Puente Navazo MD, Valmori D, Rüegg C. The alternatively spliced domain TnFnIII A1A2 of the extracellular matrix protein tenascin-C suppresses activation-induced T lymphocyte proliferation and cytokine production. J Immunol 2001;167: 6431-6440. (Pubitemid 33081576)
36. Loike JD, Cao L, Budhu S, Hoffman S, Silverstein SC. Blockade of alpha 5 beta 1 integrins reverses the inhibitory effect of tenascin on chemotaxis of human monocytes and polymorphonuclear leukocytes through three-dimensional gels of extracellular matrix proteins. J Immunol 2001;166:7534-7542. (Pubitemid 32525633)
37. Cowan KN, Jones PL, Rabinovitch M. Elastase and matrix metalloproteinase inhibitors induce regression, and tenascin-C antisense prevents progression, of vascular disease. J Clin Invest 2000;105:21-34. (Pubitemid 30036384)
38. Wallner K, Li C, Shah PK, Fishbein MC, Forrester JS, Kaul S et al. Tenascin-C is expressed in macrophage-rich human coronary atherosclerotic plaque. Circulation 1999;99:1284-1289. (Pubitemid 29129911)
39. Schenk S, Chiquet-Ehrismann R, Battegay EJ. The fibrinogen globe of tenascin-C promotes basic fibroblast growth factor-induced endothelial cell elongation. Mol Biol Cell 1999;10:2933-2943. (Pubitemid 29441573)
40. Hauzenberger D, Olivier P, Gundersen D, Rüegg C. Tenascin-C inhibits beta1 integrin-dependent T lymphocyte adhesion to fibronectin through the binding of its fnIII 1-5 repeats to fibronectin. Eur J Immunol 1999;29:1435-1447. (Pubitemid 29224448)
41. Hibino S, Kato K, Kudoh S, Yagita H, Okumura K. Tenascin suppresses CD3-mediated T cell activation. Biochem Biophys Res Commun 1998;250:119-124. (Pubitemid 28448634)
42. Clark RA, Erickson HP, Springer TA. Tenascin supports lymphocyte rolling. J Cell Biol 1997;137:755-765. (Pubitemid 27200675)
43. Gundersen D, Trân-Thang C, Sordat B, Mourali F, Rüegg C. Plasmin-induced proteolysis of tenascin-C: modulation by T lymphocyte-derived urokinase-type plasminogen activator and effect on T lymphocyte adhesion, activation, and cell clustering. J Immunol 1997;158:1051-1060. (Pubitemid 127469924)
44. Jones PL, Rabinovitch M. Tenascin-C is induced with progressive pulmonary vascular disease in rats and is functionally related to increased smooth muscle cell proliferation. Circ Res 1996;79:1131-1142. (Pubitemid 26404145)
45. Khan KM, Falcone DJ. Role of laminin in matrix induction of macrophage urokinasetype plasminogen activator and 92-kDa metalloproteinase expression. J Biol Chem 1997;272:8270-8275. (Pubitemid 27147782)
46. Chung CY, Murphy-Ullrich JE, Erickson HP. Mitogenesis, cell migration, and loss of focal adhesions induced by tenascin-C interacting with its cell surface receptor, annexin II. Mol Biol Cell 1996;7:883-892. (Pubitemid 26181724)
47. Murphy-Ullrich JE, Lightner VA, Aukhil I, Yan YZ, Erickson HP, Höök M. Focal adhesion integrity is downregulated by the alternatively spliced domain of human tenascin. J Cell Biol 1991;115:1127-1136. (Pubitemid 21909959)
48. Canfield AE, Schor AM. Evidence that tenascin and thrombospondin-1 modulate sprouting of endothelial cells. J Cell Sci 1995;108:797-809.
49. Sriramarao P, Mendler M, Bourdon MA. Endothelial cell attachment and spreading on human tenascin is mediated by alpha 2 beta 1 and alpha v beta 3 integrins. J Cell Sci 1993;105:1001-1012. (Pubitemid 23258663)
50. Rüegg CR, Chiquet-Ehrismann R, Alkan SS. Tenascin, an extracellular matrix protein, exerts immunomodulatory activities. Proc Natl Acad Sci USA 1989;86:7437-7441. (Pubitemid 19254471)
51. Midwood K, Sacre S, Piccinini AM, Inglis J, Trebaul A, Chan E et al. Tenascin-C is an endogenous activator of Toll-like receptor 4 that is essential for maintaining inflammation in arthritic joint disease. Nat Med 2009;15:774-780.
52. Sawada Y, Onoda K, Imanaka-Yoshida K, Maruyama J, Yamamoto K, Yoshida T et al. Tenascin-C synthesized in both donor grafts and recipients accelerates artery graft stenosis. Cardiovasc Res 2007;74:366-376. (Pubitemid 46693714)
53. Yamamoto K, Onoda K, Sawada Y, Fujinaga K, Imanaka-Yoshida K, Shimpo H et al. Tenascin-C is an essential factor for neointimal hyperplasia after aortotomy in mice. Cardiovasc Res 2005;65:737-742. (Pubitemid 40138995)
54. Hedin U, Holm J, Hansson GK. Induction of tenascin in rat arterial injury. Relationship to altered smooth muscle cell phenotype. Am J Pathol 1991;139:649-656.
55. Wallner K, Sharifi BG, Shah PK, Noguchi S, DeLeon H, Wilcox JN. Adventitial remodeling after angioplasty is associated with expression of tenascin mRNA by adventitial myofibroblasts. J Am Coll Cardiol 2001;37:655-661.
56. Iso Y, Suzuki H, Sato T, Shoji M, Shibata M, Shimizu N et al. The mechanism of in-stent restenosis in radius stent: an experimental porcine study. Circ J 2005;69: 481-487.
57. Wilcox JN, Okamoto EI, Nakahara KI, Vinten-Johansen J. Perivascular responses after angioplasty which may contribute to postangioplasty restenosis: a role for circulating myofibroblast precursors?. Ann N Y Acad Sci 2001;947:68-90.
58. Chaux A, Ruan XM, Fishbein MC, Ouyang Y, Kaul S, Pass JA et al. Perivascular delivery of a nitric oxide donor inhibits neointimal hyperplasia in vein grafts implanted in the arterial circulation. J Thorac Cardiovasc Surg 1998;115:604-612.
59. Nishioka T, Onishi K, Shimojo N, Nagano Y, Matsusaka H, Ikeuchi M et al. Tenascin-C may aggravate left ventricular remodeling and function after myocardial infarction in mice. Am J Physiol Heart Circ Physiol 2010;298:H1072-H1078.
60. Bujak M, Ren G, Kweon HJ, Dobaczewski M, Reddy A, Taffet G et al. Essential role of Smad3 in infarct healing and in the pathogenesis of cardiac remodeling. Circulation 2007;116:2127-2138. (Pubitemid 350060350)
61. Taki J, Inaki A,Wakabayashi H, Imanaka-Yoshida K, Ogawa K, Hiroe M et al. Dynamic expression of tenascin-C after myocardial ischemia and reperfusion: assessment by 125I-anti-tenascin-C antibody imaging. J Nucl Med 2010;51:1116-1122.
62. Odaka K, Uehara T, Arano Y, Adachi S, Tadokoro H, Yoshida K et al. Noninvasive detection of cardiac repair after acute myocardial infarction in rats by 111 In Fab fragment of monoclonal antibody specific for tenascin-C. Int Heart J 2008;49: 481-492.
63. Pak HN, Qayyum M, Kim DT, Hamabe A, Miyauchi Y, Lill MC et al. Mesenchymal stem cell injection induces cardiac nerve sprouting and increased tenascin expression in a Swine model of myocardial infarction. J Cardiovasc Electrophysiol 2003;14:841-848. (Pubitemid 36994105)
64. Laky D, Parascan L. Hibernating myocardium, morphological studies on intraoperatory myocardial biopsies and on chronic ischemia experimental model. Rom J Morphol Embryol 2007;48:407-413.
65. von Lukowicz T, Silacci M, Wyss MT, Trachsel E, Lohmann C, Buck A et al. Human antibody against C domain of tenascin-C visualizes murine atherosclerotic plaques ex vivo. J Nucl Med 2007;48:582-587. (Pubitemid 47571414)
66. Frid MG, Brunetti JA, Burke DL, Carpenter TC, Davie NJ, Reeves JT et al. Hypoxia-induced pulmonary vascular remodeling requires recruitment of circulating mesenchymal precursors of a monocyte/macrophage lineage. Am J Pathol 2006;168: 659-669. (Pubitemid 43271163)
67. Ivy DD, McMurtry IF, Colvin K, Imamura M, Oka M, Lee DS et al. Development of occlusive neointimal lesions in distal pulmonary arteries of endothelin B receptordeficient rats: a new model of severe pulmonary arterial hypertension. Circulation 2005;111:2988-2996. (Pubitemid 40814193)
68. Jones PL, Chapados R, Baldwin HS, Raff GW, Vitvitsky EV, Spray TL et al. Altered hemodynamics controls matrix metalloproteinase activity and tenascin-C expression in neonatal pig lung. Am J Physiol Lung Cell Mol Physiol 2002;282:L26-L35. (Pubitemid 34654177)
69. Lu A, Tang Y, Ran R, Clark JF, Aronow BJ, Sharp FR. Genomics of the periinfarction cortex after focal cerebral ischemia. J Cereb Blood Flow Metab 2003;23:786-810. (Pubitemid 36818687)
70. Suzuki H, Kanamaru K, Suzuki Y, Aimi Y, Matsubara N, Araki T et al. Tenascin-C is induced in cerebral vasospasm after subarachnoid hemorrhage in rats and humans: a pilot study. Neurol Res 2010;32:179-184.
71. Vyavahare N, Jones PL, Tallapragada S, Levy RJ. Inhibition of matrix metalloproteinase activity attenuates tenascin-C production and calcification of implanted purified elastin in rats. Am J Pathol 2000;157:885-893. (Pubitemid 32109381)
72. Kenji K, Hironori U, Hideya Y, Michinori I, Yasuhiko H, Nobuoki K. Tenascin-C is associated with coronary plaque instability in patients with acute coronary syndromes. Circ J 2004;68:198-203.
73. Franz M, Brehm BR, Richter P, Gruen K, Neri D, Kosmehl H et al. Changes in extra cellular matrix remodelling and re-expression of fibronectin and tenascin-C splicing variants in human myocardial tissue of the right atrial auricle: implications for a targeted therapy of cardiovascular diseases using human SIP format antibodies. J Mol Histol 2010;41:39-50.
74. Schenke-Layland K, Stock UA, Nsair A, Xie J, Angelis E, Fonseca CG et al. Cardiomyopathy is associated with structural remodelling of heart valve extracellular matrix. Eur Heart J 2009;30:2254-2265.
75. Jian B, Jones PL, Li Q, Mohler ER 3rd, Schoen FJ, Levy RJ. Matrix metalloproteinase-2 is associated with tenascin-C in calcific aortic stenosis. Am J Pathol 2001;159: 321-327. (Pubitemid 33704217)
76. Willems IE, Arends JW, Daemen MJ. Tenascin and fibronectin expression in healing human myocardial scars. J Pathol 1996;179:321-325. (Pubitemid 26266413)
77. Pedretti M, Rancic Z, Soltermann A, Herzog BA, Schliemann C, Lachat M et al. Comparative immunohistochemical staining of atherosclerotic plaques using F16, F8 and L19: Three clinical-grade fully human antibodies. Atherosclerosis 2010;208:382-389.
78. Cario-Toumaniantz C, Boularan C, Schurgers LJ, Heymann MF, Le Cunff M, Léger J et al. Identification of differentially expressed genes in human varicose veins: involvement of matrix gla protein in extracellular matrix remodeling. J Vasc Res 2007;44: 444-459. (Pubitemid 350022327)
79. Kirsch D, Schreiber J, Dienes HP, Bö ttger T, Junginger T. Alterations of the extracellular matrix of venous walls in varicous veins. VASA 1999;28:95-99. (Pubitemid 29265802)
80. Paik DC, Fu C, Bhattacharya J, Tilson MD. Ongoing angiogenesis in blood vessels of the abdominal aortic aneurysm. Exp Mol Med 2004;36:524-533. (Pubitemid 40129174)
81. Satta J, Soini Y, Pö llänen R, Pääkkö P, Juvonen T. Tenascin expression is associated with a chronic inflammatory process in abdominal aortic aneurysms. J Vasc Surg 1997;26:670-675. (Pubitemid 27459615)
82. Nataatmadja M, West M, West J, Summers K, Walker P, Nagata M et al. Abnormal extracellular matrix protein transport associated with increased apoptosis of vascular smooth muscle cells in marfan syndrome and bicuspid aortic valve thoracic aortic aneurysm. Circulation 2003;108:II329-II334. (Pubitemid 37099977)
83. Chen C, Ku DN, Kikeri D, Lumsden AB. Tenascin: a potential role in human arteriovenous PTFE graft failure. J Surg Res 1996;60:409-416. (Pubitemid 26063001)
84. Tanabe S, Ueda M, Han YS, Nakatani T, Kishimoto T, Suzuki S et al. Increased tenascin expression is an early feature of the development of transplant renal arteriopathy in humans. Transpl Int 1996;9:S45-S48.
85. Celik A, Kocyigit I, Calapkorur B, Korkmaz H, Doganay E, Elcik D et al. Tenascin-C may be a predictor of acute pulmonary thromboembolism. J Atheroscler Thromb 2011;18:478-493.
86. Schumann C, Lepper PM, Frank H, Schneiderbauer R, Wibmer T, Kropf C et al. Circulating biomarkers of tissue remodelling in pulmonary hypertension. Biomarkers 2010;15:523-532.
87. Franz M, Berndt A, Altendorf-Hofmann A, Fiedler N, Richter P, Schumm J et al. Serum levels of large tenascin-C variants, matrix metalloproteinase-9, and tissue inhibitors of matrix metalloproteinases in concentric versus eccentric left ventricular hypertrophy. Eur J Heart Fail 2009;11:1057-1062.
88. Terasaki F, Okamoto H, Onishi K, Sato A, Shimomura H, Tsukada B et al. Study Group for Intractable Diseases by a Grant from the Ministry of Health, Labor and Welfare of Japan. Higher serum tenascin-C levels reflect the severity of heart failure, left ventricular dysfunction and remodeling in patients with dilated cardiomyopathy. Circ J 2007;71:327-330. (Pubitemid 46409533)
89. Sato A, Aonuma K, Imanaka-Yoshida K, Yoshida T, Isobe M, Kawase D et al. Serum tenascin-C might be a novel predictor of left ventricular remodeling and prognosis after acute myocardial infarction. J Am Coll Cardiol 2006;47:2319-2325. (Pubitemid 43795072)
90. Aso N, Tamura A, Nasu M. Circulating tenascin-C levels in patients with idiopathic dilated cardiomyopathy. Am J Cardiol 2004;94:1468-1470. (Pubitemid 39556230)
91. Hessel MH, Bleeker GB, Bax JJ, Henneman MM, den Adel B, Klok M et al. Reverse ventricular remodelling after cardiac resynchronization therapy is associated with a reduction in serum tenascin-C and plasma matrix metalloproteinase-9 levels. Eur J Heart Fail 2007;9:1058-1063. (Pubitemid 47451814)
92. Liabeuf S, Barreto DV, Kretschmer A, Barreto FC, Renard C, Andrejak M et al. High circulating levels of large splice variants of tenascin-C is associated with mortality and cardiovascular disease in chronic kidney disease patients. Atherosclerosis 2011; 215:116-124.
93. Fujimoto N, Onishi K, Sato A, Terasaki F, Tsukada B, Nozato T et al. Incremental prognostic values of serum tenascin-C levels with blood B-type natriuretic peptide testing at discharge in patients with dilated cardiomyopathy and decompensated heart failure. J Card Fail 2009;15:898-905.
94. Gherzi R, Ponassi M, Gaggero B, Zardi L. The first untranslated exon of the human tenascin-C gene plays a regulatory role in gene transcription. FEBS Lett 1995;369: 335-339.
95. Gherzi R, Carnemolla B, Siri A, Ponassi M, Balza E, Zardi L. Human tenascin gene. Structure of the 5'-region, identification, and characterisation of the transcription regulatory sequences. J Biol Chem 1995;270:3429-3434.
96. Wallace C, Newhouse SJ, Braund P, Zhang F, Tobin M, Falchi M et al. Genome-wide association study identifies genes for biomarkers of cardiovascular disease: serum urate and dyslipidemia. Am J Hum Genet 2008;82:139-149. (Pubitemid 351735954)
97. Minear MA, Crosslin DR, Sutton BS, Connelly JJ, Nelson SC, Gadson-Watson S et al. Polymorphic variants in tenascin-C (TNC) are associated with atherosclerosis and coronary artery disease. Hum Genet 2011;129:641-654.
98. Pas J, Wyszko E, Rolle K, Rychlewski L, Nowak S, Zukiel R et al. Analysis of structure and function of tenascin-C. Int J Biochem Cell Biol 2006;38:1594-1602. (Pubitemid 43729294)
99. Bonner-Fraser M. Distribution and function of tenascin during cranial neural crest development in the chick. J Neurosci Res 1988;21:135-147.
100. Midwood KS, Orend G. The role of tenascin-C in tissue injury and tumirogenesis. J Cell Commun Signal 2009;3:287-310.
101. Borsi L, Balza E, Gaggero B, Allemanni G, Zardi L. The alternative splicing pattern of the tenascin-C pre-mRNA is controlled by the extracellular pH. J Biol Chem 1995; 270:248-254.
102. Vaughn L, Huber S, Chiquet M, Winterhalter KH. A major, six-armed glycoprotein from embryonic cartilage. EMBO J 1987;6:349-353.